Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ventilator-associated pneumonia.

Jean Chastre1, Jean-Yves Fagon

  • 1Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, France. jean.chastre@psl.ap-hop-paris.fr

American Journal of Respiratory and Critical Care Medicine
|April 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.

npj antimicrobials and resistance·2026
Same author

A consensus of European experts on the definition of ventilator-associated pneumonia recurrences obtained by the Delphi method: the RECUVAP study.

Intensive care medicine·2025
Same author

Subjective and objective survival prediction in mechanically ventilated critically ill patients: a prospective cohort study.

Critical care (London, England)·2023
Same author

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.

Critical care (London, England)·2022
Same author

Bronchoscopy for diagnosis of ventilator-associated pneumonia.

Intensive care medicine·2022
Same author

In-hospital cardiac arrests admitted alive in intensive care units: Insights from the CubRéa database.

Journal of critical care·2022
Same journal

How the Exposome Shapes Our Respiratory Health.

American journal of respiratory and critical care medicine·2026
Same journal

Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.

American journal of respiratory and critical care medicine·2026
Same journal

Opportunities for Human Lung Tissue-Based Studies in Fibrotic ILD Research.

American journal of respiratory and critical care medicine·2026
Same journal

Astegolimab in COPD: success or failure?

American journal of respiratory and critical care medicine·2026
Same journal

How artificial intelligence could improve the diagnosis and management of COPD: a perspective from GOLD.

American journal of respiratory and critical care medicine·2026
Same journal

Awake ECMO for ARDS: No Vent, No VILI, No Problem?

American journal of respiratory and critical care medicine·2026
See all related articles

Ventilator-associated pneumonia (VAP) is a serious lung infection in mechanically ventilated patients. Rapid diagnosis and targeted antibiotic selection are crucial for improving patient outcomes and reducing high mortality rates.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pulmonary Medicine

Background:

  • Ventilator-associated pneumonia (VAP) affects 8-28% of patients on mechanical ventilation (MV).
  • VAP has a high mortality rate (24-50%), significantly higher than other common infections.
  • Etiologic agents vary based on patient population, ICU stay, and prior antibiotic use.

Purpose of the Study:

  • To emphasize the importance of rapid VAP identification and accurate antimicrobial selection.
  • To compare diagnostic strategies for VAP, including bronchoscopic and non-bronchoscopic methods.
  • To guide the selection of initial antimicrobial therapy for VAP.

Main Methods:

  • Discusses bronchoscopic techniques (protected brush, bronchoalveolar lavage) for specimen collection.

Related Experiment Videos

  • Recommends non-bronchoscopic procedures or clinical scoring when bronchoscopy is unavailable.
  • Highlights factors for initial antimicrobial therapy selection.

    • Main Results:

    • Bronchoscopic techniques may offer a superior therapeutic strategy compared to clinical evaluation alone.
    • Non-bronchoscopic methods or clinical scores serve as alternatives for VAP diagnosis.
    • Initial antibiotic choice depends on institutional flora, clinical context, and drug properties.

    Conclusions:

    • Accurate diagnosis and timely, targeted antimicrobial therapy are vital for improving VAP outcomes.
    • Diagnostic approach should be tailored to resource availability (e.g., bronchoscopy).
    • Further research is needed on optimal treatment duration and monotherapy use in VAP.